@JTThibs @JACCJournals @ersied727 @KevinShahMD @Nikhil15 @md_viviana @bhtrachtenberg @docbhardwaj @justinvadermd @DLMann_MD It’s tough. Here are LIFE trial definitions of “advanced HF”. Human brains aren’t designed to keep track of this many variables si…
@AndrewJSauer @AshishCorrea @JCardFail @RyanTedfordMD @SJGreene_md @gcfmd @NMHheartdoc @JonathanDavisHF @gmac78 @DrNasrien @JJheart_doc @ShashankSinhaMD @rcstarling @noshreza Great paper! The LIFE trial will hopefully shed more light and provide more da…
@CardiacRX @accpcardprn @DaveDixonPharmD @accpambuprn The LIFE study should give us a little insight into valsartan vs. Entresto - granted it will be more of an advanced HF population... https://t.co/dehTR3wf2Y
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
RT @JACCJournals: New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in th…
New #JACCHF state-of-the-art review discusses the importance of the LIFE trial in addressing critical knowledge gap in the use of sacubitril/valsartan in advanced #HFrEF patients. Learn more: https://t.co/yeVXC54IYv #HeartFailure https://t.co/r3hNhrvSi2
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial https://t.co/reSRMUROU8
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
RT @FormigaFrancesc: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection F... https://t.co/8xRuFRpHmw
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/QI1qiTK6FS
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @coconnormd: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald…
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure:Drs. Mann and Braunwald describe the Life trial ; results are expected ACC 2021 https://t.co/J3crvRtNF2
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
RT @HanCardiomd: LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare…
LIFE trial : 24-week prospective, multicenter, double-blinded, double-dummy, active comparator trial undertaken to compare the safety, efficacy, and tolerability of S/V with those of valsartan in patients with advanced HFrEF https://t.co/p74YGz7MUR @JAC…
RT @FormigaFrancesc: Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection F... https://t.co/8xRuFRpHmw
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
RT @GiuseppeGalati_: Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35%…
Pushing the boundaries of sac/val beyond the limits: Rationale & Design of LIFE trial: Inclusion of : NYHA IV & FE<35% #AdvHF @SABOURETCardio @MarcoMetra @MicheleSenni @DrRajivsankar @rahatheart1 @AndreasGevaert @DrMarthaGulati @ShelleyZierot…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial |JACC: Heart Failure: Full discussion of this important trial and the conduct during Covid-19 on Thursday June 18 during JACC-HF journal cl…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
RT @BSHeartFailure: Hurrah! https://t.co/OnwrWiquOx
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @osmarperse: Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas c…
Tenemos un vacío en la evidencia de sacubitrilo/Valsartan y otros fármacos en falla avanzada/CF IV ! Grandes expectativas cuando se publique este LIFE trial ! @FallaCardiaca @AFBSM @clara_clarais @SIAC_cardio @sccccardio @fernanmendoza8 @heralv1985 @jd1l…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @BSHeartFailure: Hurrah! https://t.co/OnwrWiquOx
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
RT @JTLLERGO: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiolo…
Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial @SACardiologia https://t.co/Tzhm95cEWw https://t.co/S3a1S97A8x
RT @BSHeartFailure: Hurrah!
Hurrah!
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
RT @leonardo_seoane: SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @…
SV in HF with reduced EF and NYHA functional class IV. @MirtaDiez4 @lucreciamburgos @paomorejon @gonzaeperez @htp_ic @DrLbatt @DiseasesHeart @CousiratLiendro
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…
@PUNC14Julie
RT @coconnormd: Life Trial design published : join the JACC -HF virtual journal club June 18 with Drs. Braunwald and Mann and other trial…
RT @SJGreene_md: Sacubitril/Valsartan in Advanced Heart Failure with Reduced Ejection Fraction: Rationale/Design of the LIFE Trial https:/…